---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-24-000075"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:10:34.824600+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Boston Scientific resumes AVANT GUARD trial in drug-naïve persistent AFib patients

## Summary
- AVANT GUARD trial resumed after assessment of observations and DMC input.
- Study targets new population of drug-naïve patients with persistent atrial fibrillation.
- No financial impact or patient enrollment numbers disclosed.

## SEC filing metadata
- accession: 0000885725-24-000075
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572524000075/0000885725-24-000075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572524000075/bsx-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-24-000075
- JSON: https://secwatch.observer/filing/0000885725-24-000075.json
- Plain text: https://secwatch.observer/filing/0000885725-24-000075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.